A Mendelian randomisation study provided evidence for an inverse causal association of circulating linoleic acid levels with risk of ischaemic stroke, particularly large artery stroke.
Linoleic acid is an essential fatty acid involved in the human diet. Epidemiological studies have suggested an inverse association between circulating linoleic acid levels and ischaemic stroke , but it was unclear whether the observed association is causal or due to confounding or reverse causation. To evaluate the potential causal relationship between circulating linoleic acid levels and risk of ischaemic stroke, summary statistics for ischaemic stroke were obtained from the MEGASTROKE consortium . These data included 34,217 ischaemic stroke cases and 404,630 controls of European ancestry. First author Dr David Wu (University of Minnesota Medical School, MN, USA) explained that 17 single nucleotide polymorphisms (SNPs) associated with circulating linoleic acid levels were used as instrumental variables in the Mendelian randomisation analysis, with another 2 SNP sets used in sensitivity analyses.
“We found an inverse causal relationship between circulating linoleic acid levels and ischaemic stroke overall, and especially in large artery stroke,” Dr Wu said. Every 1% increase in genetically predicted linoleic acid levels was inversely associated with a 2% reduction in ischaemic stroke incidence. There was a significant causal association for large artery stroke (OR 0.95; 95% CI 0.92–0.98; P=0.00034), but not for cardioembolic stroke (OR 0.98; 95% CI 0.96–1.00; P=0.05) and small vessel stroke (OR 1.02; 95% CI 0.99–1.05; P=0.11). These findings are robust, as sensitivity analyses using 2 additional SNP sets as instrumental variables resulted in consistent findings.
- Zhang W, et al. Nutrition. 2020;79-80:110953.
- Wu D, et al. Effect Of Linoleic Acid On Ischemic Stroke: A Mendelian Randomization Study. S21.001, AAN 2021 Virtual Congress, 17-22 April.
Copyright ©2021 Medicom Medical Publishers
« No association between SSRIs and risk of ICH Next Article
Lower-sodium oxybate for hypersomnia »
Table of Contents: AAN 2021
Letter from the Editor
Interview with AAN President Dr James C. Stevens
AAN 2021 Highlights Podcast
COVID-19 and Neurology
The neurological impact of COVID-19
Chemosensory dysfunction often persistent after COVID-19
Pandemic results in decreased global stroke care
Stroke uncommon in critically ill COVID-19 patients
Cognitive Impairment and Dementias
Obstructive sleep apnoea associated with lower cognition
NfL is a better marker for neurodegeneration than T-tau
Monoclonal antibody rapidly reduces brain amyloid
Extraordinary transformation of epilepsy care in Ontario
No neurodevelopmental effects of foetal antiseizure medication
Migraine and Other Headaches
Long-term safety of atogepant as migraine prophylaxis
Dysmetabolism may drive MS progression
Predicting long-term prognosis in paediatric MS patients
Functional and survival benefits of AMX0035 in ALS
Parkinson’s Disease and Other Movement Disorders
Autoimmune mechanisms implicated in Parkinson’s disease
Novel non–D2-receptor-binding treatment for Parkinson’s disease psychosis
Troriluzole for spinocerebellar ataxia
Can linoleic acid help prevent stroke?
No association between SSRIs and risk of ICH
Vutrisiran for hATTR amyloidosis with polyneuropathy
10 kHz spinal cord stimulation for painful diabetic neuropathy
Gene therapy for Leber hereditary optic neuropathy
Lower-sodium oxybate for hypersomnia